Gene transfer therapy is one of three SMN-targeted treatment options for people with SMA resulting in improved survival and improvement or stabilisation in motor function following a one-time intravenous infusion of SMN transgenes [4]. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.